1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Demographic, clinical, and MR imaging characteristics of patients at the time of 3T MR imaging
Patients with RRMS (n = 9) Patients with SPMS (n = 7) P value^*
Age (y) 41.3 ± 6.3 (range, 32–53) 50.2 ± 6.0 (range, 41–56) .012
Sex 5 women, 4 men 6 women, 1 man NS
Years since MS onset 10.4 ± 6.2 (range, 3–20) 18.4 ± 5.2 (range, 13–28) .016
EDSS 1.9 ± 1.1 (range, 0–4) 6.0 ± 0.6 (range, 5–6.5) <.0001
PASAT 48.7 ± 12.8 (range, 22–60) 31.2 ± 8.1 (range, 21–45) .008
BPF 0.81 ± 0.05 (range, 0.76–0.92) 0.75 ± 0.04 (range, 0.71–0.81) .014
T2-LV (cm³) 11.5 ± 8.8 (range, 0.78–25.5) 12.6 ± 8.4 (range, 4.6–30.1) NS
Number of patients with CELs 1^† 0 N/A
CBHs (number) 48.9 ± 51.5 (range, 0–126) 37.4 ± 19.7 (range, 19–76) NS
CBHs (volume in cm³) 2.8 ± 3.3 (range, 0.1–9.6) 3.2 ± 2.7 (range, 0.8–8.4) NS
CBHs-LV/T2-LV (%) 16.9 ± 11.7 (range, 3–34) 24.1 ± 10.3 (range, 14–48) NS
Undergoing therapies 
    Interferon beta 3 3 
    Daclizumab 4 − 
    Other treatments − 2 
    None 2 2 
Note:—RRMS indicates relapsing-remitting multiple sclerosis; SPMS, secondary-progressive multiple sclerosis; EDSS, Expanded Disability Status Scale; PASAT, Paced Auditory Serial Addition Test; BPF, brain parenchyma fraction; T2-LV, T2 lesion volume; CELs, contrast-enhancing lesions; CBHs, chronic black holes; N/A, not applicable; NS, not significant.
* P values are significant if P ≤ .05.
† A single patient had 1 CEL in the corpus callosum (see text in the Results section).